Drug intelligence / Profile preview

KN042

Development stage: Preclinical
Lead developer: AlphaMab Oncology
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

KN042 is a biosimilar antibody candidate being developed by Suzhou Alphamab Co., Ltd. for the treatment of type 2 diabetes (T2D). As a biosimilar, it is designed to be highly similar to an already approved reference biologic, although the specific reference product and biological target have not been publicly disclosed by the sponsor. The program is currently in the lead optimization or early preclinical stage of development and is part of Alphamab's pipeline of biosimilar analogues.

Beyond the preview

Go deeper on KN042.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KN042.

Explore the full profile